Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L17 pseudogene 18 (RPL17P18) is a processed pseudogene corresponding to the ribosomal protein L17 gene (RPL17). Processed pseudogenes are genomic DNA sequences similar to normal genes but are non-functional due to the absence of regulatory elements or coding mutations, and they do not encode a functional protein. RPL17P18, like other ribosomal protein pseudogenes, does not produce protein and has no known biological activity, disease association, or therapeutic utility[7][5]. It exists as part of the large family of ribosomal protein pseudogenes scattered throughout the genome, but it is not a therapeutic target and has no associated drugs, functions, or disease roles[7][5][8]. Key clarification: RPL17P18 is not the functional ribosomal protein L17 (RPL17), which is a component of the large (60S) ribosomal subunit. Instead, it is a non-functional copy (pseudogene) and should not be considered a molecular target for therapy or drug interaction[7][5][8]. If you require information about the parent gene and the functional ribosomal protein L17, please refer to RPL17 rather than RPL17P18[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L17 pseudogene 18 (RPL17P18).